Summary:
- GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine approved in Canada, has received an expanded age indication to include adults aged 50-59 at increased risk of severe disease.
- The expanded approval is based on positive results from a phase III clinical trial, which demonstrated the vaccine's efficacy in preventing severe RSV-associated lower respiratory tract illness in this age group.
- This expanded indication will help protect a broader population of older adults in Canada who are at increased risk of severe RSV disease, providing an important new tool in the fight against this common and potentially serious respiratory infection.